{"key":"op_830_TR","page":{"url":"https://fr.bookimed.com/clinics/country=turkey/procedure=lutetium-177-therapy/","procedure":{"id":830,"slug":"lutetium-177-therapy","name":"Thérapie au lutétium-177","name_forms":{"plural":{"status":"missing","reason":"not_collected"},"genitive":{"status":"missing","reason":"not_collected"}},"type":"therapy","grammar_number":{"status":"missing","reason":"not_collected"},"parent_id":"oncology","family_attribute":{"status":"missing","reason":"not_collected"}},"country":{"id":46,"iso":"TR","name":"Turquie"},"currency":"USD","data_date":"2026-11-16"},"pages":{"clinics_url":"https://fr.bookimed.com/clinics/country=turkey/procedure=lutetium-177-therapy/","cost_url":"https://fr.bookimed.com/clinics/country=turkey/procedure=lutetium-177-therapy/cost/","best_url":{"status":"missing","reason":"template not live"}},"price":{"from":5000,"to":8800,"avg":{"value":10000,"method":"median","source":"offers"},"us":{"from":42000,"to":54000},"uk":{"from":21000,"to":31000},"by_technique":[{"technique":"Lu-177 PSMA-617 (Lu-PSMA) radioligand therapy","technique_id":"lu-177-psma-617-radioligand","price_from":10000,"currency":"USD","source":"package","offers":2,"date":"2026-11-17"},{"technique":"Lu-177 DOTATATE peptide receptor radionuclide therapy","technique_id":"lu-177-dotatate-peptide","price_from":10000,"currency":"USD","source":"package","offers":2,"date":"2026-11-17"}],"by_city":[{"city":"Istanbul","from":5000},{"city":"Antalya","from":9000},{"city":"Bursa","from":4400},{"city":"Izmir","from":4500}],"per_unit":{"status":"missing","reason":"not_collected"},"factors":{"status":"missing","reason":"not_collected"},"tiers":{"source":"offers","items":[{"tier":"standard","min":6500,"max":7500,"median":7000,"count":2},{"tier":"premium","min":10000,"max":11750,"median":10875,"count":4}]},"comparison":[{"country_iso":"UA","from":10000,"to":17000},{"country_iso":"FR","from":18000,"to":26000},{"country_iso":"GB","from":21000,"to":31000},{"country_iso":"US","from":42000,"to":54000},{"country_iso":"IL","from":16000,"to":26000},{"country_iso":"MX","from":15000,"to":22000},{"country_iso":"DE","from":17000,"to":26000},{"country_iso":"CA","from":28000,"to":45000},{"country_iso":"AE","from":9000,"to":16000},{"country_iso":"TH","from":7000,"to":9500},{"country_iso":"PL","from":6500,"to":10500},{"country_iso":"KR","from":9000,"to":14000},{"country_iso":"CZ","from":9500,"to":14500},{"country_iso":"AT","from":18000,"to":30000},{"country_iso":"ES","from":7500,"to":11000},{"country_iso":"IT","from":9500,"to":14500},{"country_iso":"CN","from":6500,"to":13000},{"country_iso":"AU","from":21000,"to":31000},{"country_iso":"IN","from":3200,"to":5200},{"country_iso":"MY","from":6500,"to":10500},{"country_iso":"VN","from":9000,"to":14000},{"country_iso":"BR","from":16000,"to":26000}],"base_country":"US","base_is_fallback":false},"savings":{"pct":88,"variant":">=15%"},"package":{"included":["Consultation with a doctor","Transfer airport-clinic-airport","Blood tests","Follow-up examination","VIP transfer (premium vehicle service, all transfers between airport, hotel and clinic)","Biochemistry blood test","Complete blood count (CBC)"],"excluded":["Accommodation is not included"],"extra_charges":{"status":"missing","reason":"not_collected"}},"clinics":{"count":21,"items":[{"id":96,"name":"Memorial Şişli Hospital","city":"Istanbul","rating":4.6,"reviews_count":437,"accreditations":["International Organization for Standardization","Joint Commission International"],"rank":1,"has_procedure":true,"why_ranked":"JCI-accredited with a nuclear medicine specialist performing 900+ procedures. Offers 4-6 therapy courses with precise Ga-68 PSMA imaging to confirm treatment suitability. Includes 1-day hospitalization per course.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":[{"id":"69cfa6076a5b507d7202aefe","price":6500,"nights":0,"included":["Consultation with a doctor","VIP transfer (premium vehicle service, all transfers between airport, hotel and clinic)"],"excluded":["Accommodation is not included"],"other_services":"Pre-treatment preparation starts the night before. Our patient is admitted to the hospital in the morning. Blood samples are taken in the patient’s room. Some medications are administered intravenously before the treatment. Around noon, once the preparation (synthesis) of the Lu-177 medication is completed, the Lu-177 therapy is administered intravenously in the patient’s room. The patient stays in the hospital for 1 night for observation. The next morning, a whole-body scintigraphy scan is performed using a gamma camera. Discharge procedures begin around noon. ⸻ Follow-up process: Blood tests are required 2 weeks and 4 weeks after the treatment. If everything is progressing well in the blood tests, the second treatment session is planned approximately 6 weeks later. For patients who successfully complete 4 treatment cycles, a Ga-68 PET/CT scan is performed to evaluate the effectiveness of the treatment."}]},{"id":87,"name":"Anadolu Medical Center","city":"Istanbul","rating":4.6,"reviews_count":544,"accreditations":["Planetree's Gold Certificate","International Accreditation System for Interventional Oncology Services (IASIOS)","Patient choice in Oncology & Hematology Oncology","Patient Choice for Basic Check-up","Johns Hopkins Medicine","Organisation of European Cancer Institutes Certificate","European Society for Medical Oncology","Joint Commission International","International Organization for Standardization","World's Best Hospitals 2026 by Newsweek"],"rank":2,"has_procedure":true,"why_ranked":"Affiliated with Johns Hopkins Medicine, JCI-accredited, and offers comprehensive diagnostic and treatment protocols with a dedicated nuclear medicine specialist.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":[{"id":"69331d0832bd63eea1ffac9d","price":10000,"price_before_discount":13000,"nights":0,"included":["Consultation with a doctor","Blood tests","Follow-up examination","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"Lutetium-177 PSMA Prostate Radioligand Therapy Program The Lutetium-177 (Lu-177) PSMA Prostate Radioligand Therapy Program is an advanced targeted treatment option for patients with metastatic, progressive, or treatment-resistant prostate cancer. This program provides a structured and carefully monitored therapeutic pathway designed for precise tumor targeting and controlled systemic treatment. Prior to therapy, previously performed PSMA PET/CT imaging is reviewed to confirm adequate PSMA receptor expression and to evaluate disease distribution. Based on this molecular imaging assessment, treatment eligibility and final therapy planning are determined individually. The therapy utilizes Lutetium-177, a beta-emitting radioisotope linked to a PSMA-targeting molecule that selectively binds to prostate cancer cells. After binding and internalization, Lutetium-177 delivers targeted radiation to tumor tissue, leading to DNA damage and controlled destruction of cancer cells while minimizing exposure to surrounding healthy tissues. The radiopharmaceutical is produced in Non-Carrier-Added (NCA) quality, providing high specific activity and optimized therapeutic performance. Due to the moderate tissue penetration range of beta radiation, Lu-177 PSMA therapy enables effective treatment of metastatic lesions while maintaining a favorable safety profile. This therapy is widely used for advanced prostate cancer patients requiring systemic targeted treatment. The program is conducted under the medical supervision of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, with more than 20 years of experience in nuclear medicine and advanced molecular imaging. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in the United States, ensuring high manufacturing standards, quality control, and traceability. Nuclear medicine consultation Comprehensive laboratory testing to assess kidney, liver, and hematologic function MAG-3 renal scintigraphy Administration of Lutetium-177 PSMA therapy Post-treatment imaging Coordinated follow-up by a nuclear medicine specialist, including verification of residual radioactivity to ensure flight compatibility The recommended stay is approximately three days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient convenience, cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure smooth and organized logistics throughout the treatment process."},{"id":"69331d0832bd63eea1ffac9b","price":10000,"nights":0,"included":["Consultation with a doctor","Blood tests","Follow-up examination","Biochemistry blood test","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"Lutetium-177 DOTA Neuroendocrine Radioligand Therapy Program The Lutetium-177 (Lu-177) DOTA Radioligand Therapy Program is an advanced targeted treatment option for patients with somatostatin receptor–positive neuroendocrine tumors. This program integrates molecular imaging assessment and systemic radioligand therapy within a structured and carefully monitored treatment pathway. Prior to therapy, previously performed DOTA PET/CT imaging is reviewed to confirm somatostatin receptor expression and evaluate disease distribution. Treatment eligibility and the final therapy decision are based on this molecular imaging assessment, ensuring an individualized and precisely targeted treatment approach. The therapy utilizes Lutetium-177, a beta-emitting radioisotope attached to a DOTA-based targeting molecule that selectively binds to somatostatin receptor–expressing tumor cells. Once internalized, Lutetium-177 releases therapeutic radiation that damages tumor cell DNA, leading to controlled tumor cell destruction. Because beta radiation has a moderate tissue penetration range, it allows effective treatment of metastatic lesions while maintaining an established and favorable safety profile. The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings more than 20 years of experience in nuclear medicine and advanced molecular imaging. All treatments are administered in a specialized nuclear medicine department under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in Belgium, Russia, and the United States, ensuring high manufacturing standards, quality control, and traceability. The radiopharmaceutical is produced in Non-Carrier-Added (NCA) quality, providing high specific activity and optimized therapeutic performance. Included Services • Nuclear medicine consultation • Blood tests (kidney, liver, hematologic profile) • MAG-3 renal scintigraphy (first cycle only, if clinically indicated) • Lutetium-177 DOTA treatment administration • Post-treatment scan • Medical follow-up by nuclear medicine specialist • Verification of residual radioactivity for flight compatibility The recommended stay is approximately three days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient convenience, cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure smooth and organized logistics throughout the treatment process."},{"id":"69331d0832bd63eea1ffac9e","price":11750,"nights":0,"included":["Consultation with a doctor","Blood tests","Follow-up examination","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"Lutetium-177 PSMA Prostate Radioligand Therapy Program with PSMA PET The Lutetium-177 (Lu-177) PSMA Radioligand Therapy Program with PSMA PET is an advanced targeted treatment option for patients with metastatic, progressive, or treatment-resistant prostate cancer. This program integrates molecular imaging and radioligand therapy within a structured and carefully monitored treatment pathway. This treatment utilizes Lutetium-177, a beta-emitting radioisotope attached to a PSMA-targeting molecule that binds specifically to prostate cancer cells. Once internalized, Lutetium-177 releases therapeutic radiation that damages tumor cell DNA, resulting in controlled tumor cell destruction. Because beta radiation has a moderate tissue penetration range, it enables effective treatment of tumor lesions while maintaining an established and favorable safety profile. Before treatment, a specialized PSMA PET/CT scan is performed at our hospital to confirm adequate PSMA receptor expression and evaluate disease distribution. Only patients who meet these molecular criteria are selected for Lutetium-177 PSMA therapy, ensuring an individualized and precisely targeted treatment approach. The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings more than 20 years of experience in nuclear medicine and advanced molecular imaging. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in Belgium, Russia, and the United States, ensuring high manufacturing standards, quality control, and traceability. The radiopharmaceutical is produced in Non-Carrier-Added (NCA) quality, providing high specific activity and optimized therapeutic performance. Included Services • Nuclear medicine consultation • Blood tests (kidney, liver, hematologic profile) • PSMA PET/CT scan for therapy eligibility assessment • MAG-3 renal scintigraphy (first cycle only, if clinically indicated) • Lutetium-177 PSMA treatment administration • Post-treatment scan • Medical follow-up by nuclear medicine specialist • Verification of residual radioactivity for flight compatibility The recommended stay is approximately four days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient comfort and convenience, cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure a smooth and well-organized treatment experience."},{"id":"69331d0832bd63eea1ffac9c","price":11750,"nights":0,"included":["Complete blood count (CBC)","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"Lutetium-177 DOTA Neuroendocrine Radioligand Therapy Program with DOTA PET The Lutetium-177 (Lu-177) DOTA Radioligand Therapy Program is an advanced targeted treatment option for patients with somatostatin receptor–positive neuroendocrine tumors. This program integrates molecular imaging assessment and systemic radioligand therapy within a structured and carefully monitored treatment pathway. Before therapy, a specialized DOTA PET/CT scan is performed and evaluated at our hospital to assess somatostatin receptor expression and determine the extent of disease. Treatment eligibility and the final therapy decision are based on this comprehensive molecular imaging assessment, ensuring that only suitable patients proceed to Lutetium-177 DOTA therapy. The therapy utilizes Lutetium-177, a beta-emitting radioisotope attached to a DOTA-based targeting molecule that selectively binds to somatostatin receptor–expressing tumor cells. Once internalized, Lutetium-177 releases therapeutic radiation that damages tumor cell DNA, leading to controlled tumor cell destruction. Because beta radiation has a moderate tissue penetration range, it allows effective treatment of metastatic lesions while maintaining an established and favorable safety profile. The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings more than 20 years of experience in nuclear medicine and advanced molecular imaging. All treatments are administered in a specialized nuclear medicine department under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in Belgium, Russia, and the United States, ensuring high manufacturing standards, quality control, and traceability. The radiopharmaceutical is produced in Non-Carrier-Added (NCA) quality, providing high specific activity and optimized therapeutic performance. Included Services • Nuclear medicine consultation • Blood tests (kidney, liver, hematologic profile) • DOTA PET/CT scan for therapy eligibility assessment • MAG-3 renal scintigraphy (first cycle only, if clinically indicated) • Lutetium-177 DOTA treatment administration • Post-treatment scan • Medical follow-up by nuclear medicine specialist • Verification of residual radioactivity for flight compatibility The recommended stay is approximately three days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient convenience, cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure smooth and organized logistics throughout the treatment process."}]},{"id":410,"name":"Memorial Bahçelievler Hospital","city":"Istanbul","rating":4.6,"reviews_count":165,"accreditations":["International Organization for Standardization","Joint Commission International"],"rank":3,"has_procedure":true,"why_ranked":"Clinic offers advanced imaging with PSMA PET-CT for precise treatment planning and has a specialized nuclear medicine department. JCI accredited with high patient recommendation rates.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":426,"name":"Hisar Hospital Intercontinental","city":"Istanbul","rating":4.5,"reviews_count":267,"accreditations":["Joint Commission International","Turkish Medical Association (Türk Tabıplerı Bırliği)","Turkish Medical Association","Patient choice in Oncology & Hematology Oncology","Best patient assistance","Best clinic for radiotherapy"],"rank":4,"has_procedure":true,"why_ranked":"JCI-accredited facility with nuclear medicine specialists. Offers personalized Lu-177 therapy plans with Ga-68 PSMA imaging for treatment assessment. Includes 1-night hospitalization and translator services.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":[{"id":"6ac4a779c752e7ea1503ef84","price":7500,"price_before_discount":8000,"nights":1,"included":["Consultation with a doctor","VIP transfer (premium vehicle service, all transfers between airport, hotel and clinic)"],"excluded":["Accommodation is not included"],"other_services":"Lutetium-177 (Lu-177) Radioligand Therapy Lutetium-177 therapy is a targeted radionuclide treatment in which a radioactive substance linked to a specific molecule binds to cancer cells and delivers radiation directly to them. The treatment is administered intravenously under the supervision of a Nuclear Medicine specialist, with monitoring before and after the procedure to ensure safety and treatment effectiveness. Package Includes: Nuclear Medicine specialist consultation Required laboratory tests and medical evaluation Lutetium-177 treatment administration Radiation safety monitoring Post-treatment medical assessment Follow-up recommendations Treatment Duration: According to the patient's clinical condition and treatment protocol Hospitalization: As required by the nuclear medicine team and radiation safety regulations"}]},{"id":7176,"name":"Memorial Göztepe Hospital","city":"Istanbul","rating":4.8,"reviews_count":9,"accreditations":{"status":"missing","reason":"not_collected"},"rank":5,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":417,"name":"Memorial Antalya Hospital","city":"Antalya","rating":4.6,"reviews_count":152,"accreditations":["Joint Commission International"],"rank":6,"has_procedure":true,"why_ranked":"EARL Theranostics certification ensures high quality standards for Lutetium-177 theranostic therapy. JCI-accredited hospital with international quality standards.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":432,"name":"Memorial Ataşehir Hospital","city":"Istanbul","rating":4.5,"reviews_count":55,"accreditations":["Joint Commission International"],"rank":7,"has_procedure":true,"why_ranked":"EARL Theranostics-certified program delivers PSMA-targeted Lu-177 therapy for metastatic prostate cancer. Nuclear medicine specialists bring theranostics expertise, supported by PET-CT imaging and JCI-accredited care.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":94,"name":"Medical Park Göztepe Hospital Complex","city":"Istanbul","rating":4.4,"reviews_count":35,"accreditations":["International Organization for Standardization","Joint Commission International","Robotic Surgery Center of Exellence","Colorectal Surgery Center for Excellence","Bariatric Surgery Center of Excellence"],"rank":8,"has_procedure":true,"why_ranked":"JCI-accredited cancer hospital with dedicated Nuclear Medicine department. Offers comprehensive Lutetium-177 treatment packages including diagnostics, therapy, and follow-up care.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":3418,"name":"Valued Med Hub Hospitals","city":"Istanbul","rating":4.9,"reviews_count":59,"accreditations":["Turkish Medical Association","International Health Tourism Authorization Certificate"],"rank":9,"has_procedure":true,"why_ranked":"Uses PET-CT imaging to track tumor response to Lutetium-177 therapy. Holds International Health Tourism Authorization from the Turkish government.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":5613,"name":"VM Medical Park Florya Hospital","city":"Istanbul","rating":5,"reviews_count":1,"accreditations":["International Organization for Standardization","Joint Commission International","Robotic Surgery Center of Exellence","Colorectal Surgery Center for Excellence","Bariatric Surgery Center of Excellence"],"rank":10,"has_procedure":true,"why_ranked":"Offers Lutetium-177 therapy with comprehensive pre-op tests and procedure-related medications. Free translation and airport transfers provided for international patients.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":5615,"name":"Medical Park Antalya Hospital Complex","city":"Antalya","rating":4.4,"reviews_count":8,"accreditations":["International Health Tourism Authorization Certificate"],"rank":11,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":276,"name":"Neolife Medical Center","city":"Istanbul","rating":4.7,"reviews_count":19,"accreditations":["International Organization for Standardization","Joint Commission International"],"rank":12,"has_procedure":true,"why_ranked":"Offers both Lu-177 and alpha-emitting Ac-225 on site, with theranostic imaging paired to treatment. Response-adapted protocol repeats PSMA PET-CT after two sessions. JCI-accredited, first in Türkiye.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":765,"name":"Istinye University Liv Hospital Bahcesehir","city":"Istanbul","rating":4.2,"reviews_count":19,"accreditations":["Best clinic for radiotherapy","Best price for PET/CT","Turkish Medical Association"],"rank":13,"has_procedure":true,"why_ranked":"Offers Lutetium-177 therapy at 7,500 USD per session with sessions every two months. Provides comprehensive oncology services including PET-CT for precise tumor detection.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":85,"name":"Medipol Mega University Hospital","city":"Istanbul","rating":4.5,"reviews_count":495,"accreditations":["Joint Commission International","Patient choice in Pediatric Oncology & Hematology Oncology"],"rank":14,"has_procedure":true,"why_ranked":"Performs Ga-68 PSMA scans before treatment planning with a dedicated Nuclear Medicine department. JCI accredited with advanced imaging and therapy equipment.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":1173,"name":"Emsey Hospital","city":"Istanbul","rating":4.1,"reviews_count":42,"accreditations":["The Baby-friendly Hospital Initiative (BFHI) by WHO and UNICEF","Turkish Medical Association","TEMOS International Healthcare Accreditation","Certification according to DIN EN ISO 9001 by TÜV NORD CERT","International Health Tourism Authorization Certificate","International Organization for Standardization"],"rank":15,"has_procedure":true,"why_ranked":"Specialists in nuclear medicine perform targeted lutetium treatments with planned sessions every 6 weeks. The hospital has JCI accreditation and dedicated nuclear medicine department.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":1547,"name":"Estophia Hospital","city":"Istanbul","rating":4.4,"reviews_count":49,"accreditations":{"status":"missing","reason":"not_collected"},"rank":16,"has_procedure":true,"why_ranked":"Offers Lutetium-177 therapy with comprehensive package including preoperative tests, doctor fees, and 5* hotel accommodation. Managed by an experienced radiation oncologist with 29 years of experience.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":1169,"name":"Hermes Clinics (Hermes Clinics A.Ş.)","city":"Ankara","rating":4.5,"reviews_count":20,"accreditations":["Joint Commission International"],"rank":17,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":3887,"name":"Private Koru Ankara Hospital","city":"Ankara","rating":2,"reviews_count":1,"accreditations":["Turkish Medical Association","Joint Commission International"],"rank":18,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":1602,"name":"Acibadem Altunizade Clinic","city":"Istanbul","rating":4.4,"reviews_count":7,"accreditations":["International Organization for Standardization","Joint Commission International","LEED Platinum Sertificate for ECO Buildings"],"rank":19,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":4078,"name":"Uniqacare Clinic","city":"Istanbul","rating":{"status":"missing","reason":"not_collected"},"reviews_count":{"status":"missing","reason":"not_collected"},"accreditations":["Turkish Medical Association"],"rank":20,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":4464,"name":"Private Medicabil Hospital","city":"Bursa","rating":{"status":"missing","reason":"not_collected"},"reviews_count":{"status":"missing","reason":"not_collected"},"accreditations":["International Organization for Standardization","International Health Tourism Authorization Certificate","Joint Commission International"],"rank":21,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}}]},"doctors":{"count":10,"languages":{"status":"missing","reason":"not_collected"}},"cities":[{"id":107,"slug":"istanbul","name":"Istanbul","clinics_count":8,"price_from":5000,"profile":{"city_type":"Largest city in Turkey, megacity","access":["Sabiha Gökçen Airport (SAW), 32 km southeast of city center"],"sources":["https://en.wikipedia.org/wiki/Istanbul","https://en.wikipedia.org/wiki/Sabiha_G%C3%B6k%C3%A7en_International_Airport"],"checked_at":"2026-11-03","status":"ok"}},{"id":382,"slug":"antalya","name":"Antalya","clinics_count":2,"price_from":9000,"profile":{"city_type":"Major Mediterranean coastal city in Turkey","access":["Antalya Airport (AYT), 13 km from the city center"],"sources":["https://en.wikipedia.org/wiki/Antalya","https://en.wikipedia.org/wiki/Antalya_Airport"],"checked_at":"2026-11-03","status":"ok"}},{"id":348,"slug":"bursa","name":"Bursa","clinics_count":{"status":"missing","reason":"not_collected"},"price_from":4400,"profile":{"city_type":"City in northwestern Turkey","access":["Yenişehir Airport (YEI), 49 km from the city center"],"sources":["https://en.wikipedia.org/wiki/Bursa"],"checked_at":"2026-11-03","status":"ok"}},{"id":395,"slug":"izmir","name":"Izmir","clinics_count":{"status":"missing","reason":"not_collected"},"price_from":4500,"profile":{"city_type":"Aegean coastal port city in Turkey","access":["Izmir Airport (ADB), 14 km from the city center"],"sources":["https://en.wikipedia.org/wiki/%C4%B0zmir","https://en.wikipedia.org/wiki/Izmir_Adnan_Menderes_Airport"],"checked_at":"2026-11-03","status":"ok"}}],"offers":{"active":6,"active_with_related":6,"hospital_nights_median":0,"days_in_country_median":{"status":"missing","reason":"fewer than 10 offers with hotel days"},"top_offers":[{"id":"69cfa6076a5b507d7202aefe","clinic_id":96,"clinic_listed":true,"price":6500,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Consultation with a doctor","VIP transfer (premium vehicle service, all transfers between airport, hotel and clinic)"],"excluded":["Accommodation is not included"],"other_services":"Pre-treatment preparation starts the night before. Our patient is admitted to the hospital in the morning. Blood samples are taken in the patient’s room. Some medications are administered intravenously before the treatment. Around noon, once the preparation (synthesis) of the Lu-177 medication is completed, the Lu-177 therapy is administered intravenously in the patient’s room. The patient stays in the hospital for 1 night for observation. The next morning, a whole-body scintigraphy scan is performed using a gamma camera. Discharge procedures begin around noon. ⸻ Follow-up process: Blood tests are required 2 weeks and 4 weeks after the treatment. If everything is progressing well in the blood tests, the second treatment session is planned approximately 6 weeks later. For patients who successfully complete 4 treatment cycles, a Ga-68 PET/CT scan is performed to evaluate the effectiveness of the treatment.","is_package":true},{"id":"69331d0832bd63eea1ffac9b","clinic_id":87,"clinic_listed":true,"price":10000,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Consultation with a doctor","Blood tests","Follow-up examination","Biochemistry blood test","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"Lutetium-177 DOTA Neuroendocrine Radioligand Therapy Program The Lutetium-177 (Lu-177) DOTA Radioligand Therapy Program is an advanced targeted treatment option for patients with somatostatin receptor–positive neuroendocrine tumors. This program integrates molecular imaging assessment and systemic radioligand therapy within a structured and carefully monitored treatment pathway. Prior to therapy, previously performed DOTA PET/CT imaging is reviewed to confirm somatostatin receptor expression and evaluate disease distribution. Treatment eligibility and the final therapy decision are based on this molecular imaging assessment, ensuring an individualized and precisely targeted treatment approach. The therapy utilizes Lutetium-177, a beta-emitting radioisotope attached to a DOTA-based targeting molecule that selectively binds to somatostatin receptor–expressing tumor cells. Once internalized, Lutetium-177 releases therapeutic radiation that damages tumor cell DNA, leading to controlled tumor cell destruction. Because beta radiation has a moderate tissue penetration range, it allows effective treatment of metastatic lesions while maintaining an established and favorable safety profile. The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings more than 20 years of experience in nuclear medicine and advanced molecular imaging. All treatments are administered in a specialized nuclear medicine department under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in Belgium, Russia, and the United States, ensuring high manufacturing standards, quality control, and traceability. The radiopharmaceutical is produced in Non-Carrier-Added (NCA) quality, providing high specific activity and optimized therapeutic performance. Included Services • Nuclear medicine consultation • Blood tests (kidney, liver, hematologic profile) • MAG-3 renal scintigraphy (first cycle only, if clinically indicated) • Lutetium-177 DOTA treatment administration • Post-treatment scan • Medical follow-up by nuclear medicine specialist • Verification of residual radioactivity for flight compatibility The recommended stay is approximately three days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient convenience, cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure smooth and organized logistics throughout the treatment process.","is_package":true},{"id":"6ac4a779c752e7ea1503ef84","clinic_id":426,"clinic_listed":true,"price":7500,"price_before_discount":8000,"nights":1,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Consultation with a doctor","VIP transfer (premium vehicle service, all transfers between airport, hotel and clinic)"],"excluded":["Accommodation is not included"],"other_services":"Lutetium-177 (Lu-177) Radioligand Therapy Lutetium-177 therapy is a targeted radionuclide treatment in which a radioactive substance linked to a specific molecule binds to cancer cells and delivers radiation directly to them. The treatment is administered intravenously under the supervision of a Nuclear Medicine specialist, with monitoring before and after the procedure to ensure safety and treatment effectiveness. Package Includes: Nuclear Medicine specialist consultation Required laboratory tests and medical evaluation Lutetium-177 treatment administration Radiation safety monitoring Post-treatment medical assessment Follow-up recommendations Treatment Duration: According to the patient's clinical condition and treatment protocol Hospitalization: As required by the nuclear medicine team and radiation safety regulations","is_package":true}],"packages":[{"id":"69cfa6076a5b507d7202aefe","clinic_id":96,"clinic_listed":true,"price":6500,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Consultation with a doctor","VIP transfer (premium vehicle service, all transfers between airport, hotel and clinic)"],"excluded":["Accommodation is not included"],"other_services":"Pre-treatment preparation starts the night before. Our patient is admitted to the hospital in the morning. Blood samples are taken in the patient’s room. Some medications are administered intravenously before the treatment. Around noon, once the preparation (synthesis) of the Lu-177 medication is completed, the Lu-177 therapy is administered intravenously in the patient’s room. The patient stays in the hospital for 1 night for observation. The next morning, a whole-body scintigraphy scan is performed using a gamma camera. Discharge procedures begin around noon. ⸻ Follow-up process: Blood tests are required 2 weeks and 4 weeks after the treatment. If everything is progressing well in the blood tests, the second treatment session is planned approximately 6 weeks later. For patients who successfully complete 4 treatment cycles, a Ga-68 PET/CT scan is performed to evaluate the effectiveness of the treatment.","is_package":true},{"id":"69331d0832bd63eea1ffac9d","clinic_id":87,"clinic_listed":true,"price":10000,"price_before_discount":13000,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Consultation with a doctor","Blood tests","Follow-up examination","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"Lutetium-177 PSMA Prostate Radioligand Therapy Program The Lutetium-177 (Lu-177) PSMA Prostate Radioligand Therapy Program is an advanced targeted treatment option for patients with metastatic, progressive, or treatment-resistant prostate cancer. This program provides a structured and carefully monitored therapeutic pathway designed for precise tumor targeting and controlled systemic treatment. Prior to therapy, previously performed PSMA PET/CT imaging is reviewed to confirm adequate PSMA receptor expression and to evaluate disease distribution. Based on this molecular imaging assessment, treatment eligibility and final therapy planning are determined individually. The therapy utilizes Lutetium-177, a beta-emitting radioisotope linked to a PSMA-targeting molecule that selectively binds to prostate cancer cells. After binding and internalization, Lutetium-177 delivers targeted radiation to tumor tissue, leading to DNA damage and controlled destruction of cancer cells while minimizing exposure to surrounding healthy tissues. The radiopharmaceutical is produced in Non-Carrier-Added (NCA) quality, providing high specific activity and optimized therapeutic performance. Due to the moderate tissue penetration range of beta radiation, Lu-177 PSMA therapy enables effective treatment of metastatic lesions while maintaining a favorable safety profile. This therapy is widely used for advanced prostate cancer patients requiring systemic targeted treatment. The program is conducted under the medical supervision of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, with more than 20 years of experience in nuclear medicine and advanced molecular imaging. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in the United States, ensuring high manufacturing standards, quality control, and traceability. Nuclear medicine consultation Comprehensive laboratory testing to assess kidney, liver, and hematologic function MAG-3 renal scintigraphy Administration of Lutetium-177 PSMA therapy Post-treatment imaging Coordinated follow-up by a nuclear medicine specialist, including verification of residual radioactivity to ensure flight compatibility The recommended stay is approximately three days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient convenience, cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure smooth and organized logistics throughout the treatment process.","is_package":true},{"id":"69331d0832bd63eea1ffac9b","clinic_id":87,"clinic_listed":true,"price":10000,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Consultation with a doctor","Blood tests","Follow-up examination","Biochemistry blood test","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"Lutetium-177 DOTA Neuroendocrine Radioligand Therapy Program The Lutetium-177 (Lu-177) DOTA Radioligand Therapy Program is an advanced targeted treatment option for patients with somatostatin receptor–positive neuroendocrine tumors. This program integrates molecular imaging assessment and systemic radioligand therapy within a structured and carefully monitored treatment pathway. Prior to therapy, previously performed DOTA PET/CT imaging is reviewed to confirm somatostatin receptor expression and evaluate disease distribution. Treatment eligibility and the final therapy decision are based on this molecular imaging assessment, ensuring an individualized and precisely targeted treatment approach. The therapy utilizes Lutetium-177, a beta-emitting radioisotope attached to a DOTA-based targeting molecule that selectively binds to somatostatin receptor–expressing tumor cells. Once internalized, Lutetium-177 releases therapeutic radiation that damages tumor cell DNA, leading to controlled tumor cell destruction. Because beta radiation has a moderate tissue penetration range, it allows effective treatment of metastatic lesions while maintaining an established and favorable safety profile. The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings more than 20 years of experience in nuclear medicine and advanced molecular imaging. All treatments are administered in a specialized nuclear medicine department under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in Belgium, Russia, and the United States, ensuring high manufacturing standards, quality control, and traceability. The radiopharmaceutical is produced in Non-Carrier-Added (NCA) quality, providing high specific activity and optimized therapeutic performance. Included Services • Nuclear medicine consultation • Blood tests (kidney, liver, hematologic profile) • MAG-3 renal scintigraphy (first cycle only, if clinically indicated) • Lutetium-177 DOTA treatment administration • Post-treatment scan • Medical follow-up by nuclear medicine specialist • Verification of residual radioactivity for flight compatibility The recommended stay is approximately three days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient convenience, cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure smooth and organized logistics throughout the treatment process.","is_package":true},{"id":"69331d0832bd63eea1ffac9e","clinic_id":87,"clinic_listed":true,"price":11750,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Consultation with a doctor","Blood tests","Follow-up examination","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"Lutetium-177 PSMA Prostate Radioligand Therapy Program with PSMA PET The Lutetium-177 (Lu-177) PSMA Radioligand Therapy Program with PSMA PET is an advanced targeted treatment option for patients with metastatic, progressive, or treatment-resistant prostate cancer. This program integrates molecular imaging and radioligand therapy within a structured and carefully monitored treatment pathway. This treatment utilizes Lutetium-177, a beta-emitting radioisotope attached to a PSMA-targeting molecule that binds specifically to prostate cancer cells. Once internalized, Lutetium-177 releases therapeutic radiation that damages tumor cell DNA, resulting in controlled tumor cell destruction. Because beta radiation has a moderate tissue penetration range, it enables effective treatment of tumor lesions while maintaining an established and favorable safety profile. Before treatment, a specialized PSMA PET/CT scan is performed at our hospital to confirm adequate PSMA receptor expression and evaluate disease distribution. Only patients who meet these molecular criteria are selected for Lutetium-177 PSMA therapy, ensuring an individualized and precisely targeted treatment approach. The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings more than 20 years of experience in nuclear medicine and advanced molecular imaging. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in Belgium, Russia, and the United States, ensuring high manufacturing standards, quality control, and traceability. The radiopharmaceutical is produced in Non-Carrier-Added (NCA) quality, providing high specific activity and optimized therapeutic performance. Included Services • Nuclear medicine consultation • Blood tests (kidney, liver, hematologic profile) • PSMA PET/CT scan for therapy eligibility assessment • MAG-3 renal scintigraphy (first cycle only, if clinically indicated) • Lutetium-177 PSMA treatment administration • Post-treatment scan • Medical follow-up by nuclear medicine specialist • Verification of residual radioactivity for flight compatibility The recommended stay is approximately four days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient comfort and convenience, cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure a smooth and well-organized treatment experience.","is_package":true},{"id":"69331d0832bd63eea1ffac9c","clinic_id":87,"clinic_listed":true,"price":11750,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Complete blood count (CBC)","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"Lutetium-177 DOTA Neuroendocrine Radioligand Therapy Program with DOTA PET The Lutetium-177 (Lu-177) DOTA Radioligand Therapy Program is an advanced targeted treatment option for patients with somatostatin receptor–positive neuroendocrine tumors. This program integrates molecular imaging assessment and systemic radioligand therapy within a structured and carefully monitored treatment pathway. Before therapy, a specialized DOTA PET/CT scan is performed and evaluated at our hospital to assess somatostatin receptor expression and determine the extent of disease. Treatment eligibility and the final therapy decision are based on this comprehensive molecular imaging assessment, ensuring that only suitable patients proceed to Lutetium-177 DOTA therapy. The therapy utilizes Lutetium-177, a beta-emitting radioisotope attached to a DOTA-based targeting molecule that selectively binds to somatostatin receptor–expressing tumor cells. Once internalized, Lutetium-177 releases therapeutic radiation that damages tumor cell DNA, leading to controlled tumor cell destruction. Because beta radiation has a moderate tissue penetration range, it allows effective treatment of metastatic lesions while maintaining an established and favorable safety profile. The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings more than 20 years of experience in nuclear medicine and advanced molecular imaging. All treatments are administered in a specialized nuclear medicine department under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in Belgium, Russia, and the United States, ensuring high manufacturing standards, quality control, and traceability. The radiopharmaceutical is produced in Non-Carrier-Added (NCA) quality, providing high specific activity and optimized therapeutic performance. Included Services • Nuclear medicine consultation • Blood tests (kidney, liver, hematologic profile) • DOTA PET/CT scan for therapy eligibility assessment • MAG-3 renal scintigraphy (first cycle only, if clinically indicated) • Lutetium-177 DOTA treatment administration • Post-treatment scan • Medical follow-up by nuclear medicine specialist • Verification of residual radioactivity for flight compatibility The recommended stay is approximately three days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient convenience, cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure smooth and organized logistics throughout the treatment process.","is_package":true},{"id":"6ac4a779c752e7ea1503ef84","clinic_id":426,"clinic_listed":true,"price":7500,"price_before_discount":8000,"nights":1,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Consultation with a doctor","VIP transfer (premium vehicle service, all transfers between airport, hotel and clinic)"],"excluded":["Accommodation is not included"],"other_services":"Lutetium-177 (Lu-177) Radioligand Therapy Lutetium-177 therapy is a targeted radionuclide treatment in which a radioactive substance linked to a specific molecule binds to cancer cells and delivers radiation directly to them. The treatment is administered intravenously under the supervision of a Nuclear Medicine specialist, with monitoring before and after the procedure to ensure safety and treatment effectiveness. Package Includes: Nuclear Medicine specialist consultation Required laboratory tests and medical evaluation Lutetium-177 treatment administration Radiation safety monitoring Post-treatment medical assessment Follow-up recommendations Treatment Duration: According to the patient's clinical condition and treatment protocol Hospitalization: As required by the nuclear medicine team and radiation safety regulations","is_package":true}],"related_packages":{"status":"missing","reason":"not_collected"},"other_packages":{"status":"missing","reason":"not_classified"}},"medical":{"indications":["Metastatic castration-resistant prostate cancer with PSMA-positive disease (Lu-PSMA)","Well-differentiated gastroenteropancreatic neuroendocrine tumours with somatostatin receptor expression (Lu-DOTATATE)","Progressive inoperable/metastatic disease after other therapies, imaging-confirmed uptake"],"contraindications":["Pregnancy (absolute)","Breastfeeding (must be stopped)","Lack of target uptake on PSMA or somatostatin receptor imaging","Severe bone marrow suppression","Severely impaired kidney function (relative or absolute depending on severity)","Severe liver dysfunction","Urinary obstruction or incontinence (relative)","Life expectancy too short to benefit"],"operation_hours":{"min":1,"max":5,"unit":"hours","qualifier":"Lu-PSMA visit takes about 1–3 hours; Lu-DOTATATE visit about 4–5 hours including amino acid infusion and observation."},"anesthesia":["none"],"sessions_or_stages":{"sessions":{"min":4,"max":6,"unit":"visits","qualifier":"Treatment cycles in a typical course; actual number depends on protocol, response and tolerance."},"stages":[{"code":"cycle_1","label":"First infusion cycle","after":{"min":0,"max":0,"unit":"days","qualifier":"Start of treatment."}},{"code":"subsequent_cycles","label":"Subsequent cycles repeated every 6 to 8 weeks","after":{"min":42,"max":56,"unit":"days","qualifier":"Second cycle timing from the first; later cycles follow at similar intervals."}}],"qualifier":"Typical protocols use 4 to 6 cycles at 6 to 8 week intervals, depending on the radioligand."},"hospital_nights":{"value":0,"source":"offers","parsed_details":{"min":0,"max":1,"unit":"nights","qualifier":"Per cycle; usually same-day discharge; isolation stay may be needed under radiation rules."}},"treatment_conditions":["day_case"],"rehabilitation_days":{"min":2,"max":7,"unit":"days","qualifier":"Ordinary functional recovery after each cycle, mainly fatigue resolving."},"fly_home_after_days":{"min":1,"max":2,"unit":"days","qualifier":"Usually the day after infusion once radiation-release criteria are met; air travel may trigger detectors, so carry a treatment letter."},"back_to_work_days":{"min":1,"max":7,"unit":"days","qualifier":"Most resume office work within days; local radiation-safety rules limiting close contact may apply."},"exercise_resume_weeks":{"min":0,"max":1,"unit":"weeks","qualifier":"Light activity usually resumes within days as fatigue allows; depends on tolerance and radiation precautions."},"final_result_months":{"min":3,"max":6,"unit":"months","qualifier":"Typical time to assess response after a full course of cycles, with imaging and biomarkers; varies by disease."},"result_longevity":"The effect is disease control, not a cure. How long it lasts varies by disease, radioligand, disease burden and line of therapy.","main_risks":["Fatigue and nausea","Bone marrow suppression (anaemia, low platelets, low white cells)","Dry mouth (Lu-PSMA)","Kidney toxicity","Rare liver toxicity","Tumour flare or hormonal crisis (neuroendocrine tumours)","Rare long-term myelodysplastic syndrome or leukaemia","Radiation exposure to others, needing precautions"],"complication_rate_pct":{"min":10,"max":55,"unit":"percent","qualifier":"Grade 3-4 adverse events in pivotal trials, mainly blood count drops; mild fatigue and nausea are far more common."},"revision_rate_pct":{"status":"missing","reason":"not_collected"},"success":{"metric":"Progression-free survival at 20 months with Lu-177-DOTATATE versus high-dose octreotide (control 10.8%)","value":65.2,"horizon":"20 months","source":{"status":"missing","reason":"not_collected"},"evidence_status":"proven"},"scars":"There are no scars; the only mark is a small puncture site from the intravenous cannula.","pain":"Minimal procedural pain, only from IV cannulation; some patients have transient bone pain flare or nausea after infusion.","preparation":["Confirm target expression on PSMA or somatostatin receptor PET imaging","Baseline blood counts, kidney and liver function tests","Hydration on the day of treatment","Amino acid infusion for kidney protection (Lu-DOTATATE)","Anti-nausea medication before infusion","Review of current medications by the treating team"],"recovery_timeline":[{"phase":"Day of infusion","description":"IV infusion over about 30 minutes to 4 hours depending on protocol, with observation, then discharge.","restrictions":["Follow radiation safety precautions","Use a separate toilet where possible and flush twice"]},{"phase":"First week","description":"Possible fatigue, nausea and dry mouth; radiation precautions continue.","restrictions":["Limit close contact with others as instructed","Avoid contact with pregnant women and children as instructed"]},{"phase":"Weeks 2 to 6","description":"Blood count nadir and monitoring; fatigue gradually improves before the next cycle. Report fever, bleeding or severe fatigue.","restrictions":{"status":"missing","reason":"not_collected"}}],"follow_up_visits":[{"purpose":"assessment","requirement":"routine","after":{"min":14,"max":28,"unit":"days","qualifier":"Blood tests (blood counts, kidney and liver function) in the weeks after the first cycle."}},{"purpose":"result_review","requirement":"routine","after":{"min":84,"max":180,"unit":"days","qualifier":"Response imaging and biomarkers after the cycles are completed."}}],"sources":{"status":"missing","reason":"not_collected"},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Check the qualifications of the medical team treating you","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Have you checked the qualifications of the medical team treating you?","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C2","text":"Ask the treating doctor your questions about the treatment","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Have you been able to ask them questions about your treatment?","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C3","text":"Ask whether a doctor is always present in the clinic and whether a high dependency or intensive care unit exists","scope":"treatment_abroad","source":{"url":"https://www.bapras.org.uk/public/patient-information/cosmetic-surgery/cosmetic-surgery-abroad","host":"bapras.org.uk","quote":"Is there always a doctor in the clinic and is there a high dependency or intensive care unit?","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C4","text":"Confirm the surgeon is trained and experienced in the exact procedure you are considering, not just in surgery generally","scope":"treatment_abroad","source":{"url":"https://www.isaps.org/discover/patients-home/considering-your-procedure-abroad/finding-a-surgeon-abroad/","host":"isaps.org","quote":"Verify that the surgeon is trained and experienced in performing the procedure you are considering.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C5","text":"Expect two consultations with the treating surgeon before any surgery, which also gives you time to reconsider","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/conditions/cosmetic-procedures/cosmetic-surgery-abroad/","host":"nhs.uk","quote":"You should have 2 consultations with the surgeon treating you before any surgery.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"Only a helpline, not a named doctor, is offered for complications","scope":"treatment_abroad","source":{"url":"https://www.rcseng.ac.uk/patient-care/cosmetic-surgery/having-surgery-abroad","host":"rcseng.ac.uk","quote":"Make sure you have the contact details of a named doctor who can deal with any complications rather than a helpline.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"F2","text":"An advert or information that guarantees complete success should raise concerns","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Any advert or information that guarantees complete success should raise concerns.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F3","text":"Forceful persuasion or cheap, time-limited offers pushing you into a quick decision","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"warning_signs":{"status":"ok","items":[{"id":"W1","text":"Vomiting blood or bleeding you cannot stop","urgency":"emergency","general":false,"source":{"url":"https://www.mskcc.org/cancer-care/patient-education/medications/adult/lutetium-lu-177-vipivotide-tetraxetan","host":"mskcc.org","quote":"Signs of bleeding like throwing up or coughing up blood; vomit that looks like coffee grounds; blood in the urine; black, red, or tarry stools; bleeding from the gums; abnormal vaginal bleeding; bruises without a cause or that get bigger; or bleeding you cannot stop.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W2","text":"Unable to pass urine","urgency":"contact_clinic","general":false,"source":{"url":"https://www.mskcc.org/cancer-care/patient-education/medications/adult/lutetium-lu-177-vipivotide-tetraxetan","host":"mskcc.org","quote":"Signs of kidney problems like unable to pass urine, change in how much urine is passed, blood in the urine, or a big weight gain.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W3","text":"Fever, chills, or sore throat","urgency":"contact_clinic","general":true,"source":{"url":"https://my.clevelandclinic.org/health/drugs/23722-lutetium-lu-177-vipivotide-tetraxetan-injection","host":"my.clevelandclinic.org","quote":"Call your care team for advice if you get a fever, chills, sore throat, or other symptoms of a cold or flu.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"take_home":{"status":"ok","items":[{"id":"T1","text":"Tells home clinicians radiation may persist up to two months after therapy","document":"radioactive medicine card","source":{"url":"https://www.mskcc.org/cancer-care/patient-education/about-your-pluvicto-treatment","host":"mskcc.org","quote":"It says you can give off small amounts of radioactivity for up to 2 months after your treatment.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T2","text":"Home doctor needs the clinic's follow-up recommendations in a written discharge summary","document":"discharge summary","source":{"url":"https://sbuhb.nhs.wales/about-us/individual-patient-commissioning/ipc-folder/advice-on-accessing-treatment-abroad","host":"sbuhb.nhs.wales","quote":"When you have treatment abroad, you must ask the treatment provider for their follow-up recommendations documented within a written discharge summary in English.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"preop_tests":{"status":"ok","items":[{"id":"T1","name":"PET scan","aliases":["PET scan","PSMA PET","DOTATATE PET","somatostatin receptor PET imaging","PET imaging","PET/CT"],"kind":"imaging","origin":[{"field":"preparation","text":"Confirm target expression on PSMA or somatostatin receptor PET imaging"},{"field":"initial_assessment_documents","text":"PSMA or DOTATATE PET/CT report and images"}],"what_it_checks":{"text":"Shows where the tumor is and how well the ligand binds","source":{"url":"https://snmmi.org/MWM/Patients/Procedures/177Lu-PSMA-617-Therapy-Pluvicto.aspx","host":"snmmi.org","quote":"The PSMA ligand is similar to the one used for therapy but uses a different type of radioactive material that provides an image (PET/CT) to show where the tumor is and how well the ligand attaches to it.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":{"text":"Wait 45 to 60 minutes after the arm vein injection before the scan","source":{"url":"https://snmmi.org/MWM/Patients/Procedures/177Lu-PSMA-617-Therapy-Pluvicto.aspx","host":"snmmi.org","quote":"For this procedure, you will receive an injection into an arm vein and will wait 45-60 minutes to allow it to circulate before undergoing the scan.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}}},{"id":"T2","name":"Complete blood count","aliases":["Complete blood count","CBC","blood counts","full blood count"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood counts, kidney and liver function tests"},{"field":"initial_assessment_documents","text":"Recent blood counts and kidney function tests"}],"what_it_checks":{"text":"Checks red cells, white cells and platelets, which therapy can lower","source":{"url":"https://snmmi.org/MWM/Patients/Procedures/177Lu-PSMA-617-Therapy-Pluvicto.aspx","host":"snmmi.org","quote":"The radiation may cause a decrease in your red cells, white cells, platelets, liver or kidney function.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"type":"always","text":"Always","source":{"url":"https://snmmi.org/MWM/Patients/Procedures/177Lu-PSMA-617-Therapy-Pluvicto.aspx","host":"snmmi.org","quote":"Several days before each treatment, you will need to undergo blood to make sure it is safe to proceed.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"test_prep":null},{"id":"T3","name":"Kidney function test","aliases":["Kidney function test","kidney function tests","renal function test","renal function tests"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood counts, kidney and liver function tests"},{"field":"initial_assessment_documents","text":"Recent blood counts and kidney function tests"}],"what_it_checks":{"text":"Checks kidney function, which the radiation can decrease","source":{"url":"https://snmmi.org/MWM/Patients/Procedures/177Lu-PSMA-617-Therapy-Pluvicto.aspx","host":"snmmi.org","quote":"The radiation may cause a decrease in your red cells, white cells, platelets, liver or kidney function.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"type":"always","text":"Always","source":{"url":"https://snmmi.org/MWM/Patients/Procedures/177Lu-PSMA-617-Therapy-Pluvicto.aspx","host":"snmmi.org","quote":"Several days before each treatment, you will need to undergo blood to make sure it is safe to proceed.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"test_prep":null},{"id":"T4","name":"Liver function test","aliases":["Liver function test","liver function tests","LFT","LFTs"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood counts, kidney and liver function tests"},{"field":"initial_assessment_documents","text":"Liver function tests"}],"what_it_checks":{"text":"Checks liver function, which the radiation can decrease","source":{"url":"https://snmmi.org/MWM/Patients/Procedures/177Lu-PSMA-617-Therapy-Pluvicto.aspx","host":"snmmi.org","quote":"The radiation may cause a decrease in your red cells, white cells, platelets, liver or kidney function.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"type":"always","text":"Always","source":{"url":"https://snmmi.org/MWM/Patients/Procedures/177Lu-PSMA-617-Therapy-Pluvicto.aspx","host":"snmmi.org","quote":"Several days before each treatment, you will need to undergo blood to make sure it is safe to proceed.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"test_prep":null},{"id":"T5","name":"CT scan","aliases":["CT scan","CT","computed tomography"],"kind":"imaging","origin":[{"field":"initial_assessment_documents","text":"Recent CT or MRI reports (if available)"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T6","name":"MRI scan","aliases":["MRI scan","MRI","magnetic resonance imaging"],"kind":"imaging","origin":[{"field":"initial_assessment_documents","text":"Recent CT or MRI reports (if available)"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T7","name":"Blood tests","aliases":["Blood tests"],"kind":"lab","origin":[{"field":"packages","text":"Blood tests"}],"what_it_checks":{"text":"Checks red cells, white cells, platelets, liver and kidney function","source":{"url":"https://snmmi.org/MWM/Patients/Procedures/177Lu-PSMA-617-Therapy-Pluvicto.aspx","host":"snmmi.org","quote":"These include tests for your red cells, white cells, platelets, liver and kidney function.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"type":"always","text":"Always","source":{"url":"https://snmmi.org/MWM/Patients/Procedures/177Lu-PSMA-617-Therapy-Pluvicto.aspx","host":"snmmi.org","quote":"Several days before each treatment, you will need to undergo blood to make sure it is safe to proceed.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"test_prep":{"text":"Have blood testing several days before each treatment","source":{"url":"https://snmmi.org/MWM/Patients/Procedures/177Lu-PSMA-617-Therapy-Pluvicto.aspx","host":"snmmi.org","quote":"Several days before each treatment, you will need to undergo blood to make sure it is safe to proceed.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}}}],"checked_at":"2026-11-17","next_check_at":"2027-11-17","version":1},"prep_in_advance":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-17","next_check_at":"2027-02-15"},"visit_and_day":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-17","next_check_at":"2027-02-15"},"if_something_changes":{"status":"ok","items":[{"id":"S1","text":"Pregnancy or breastfeeding should be reported because Lu-177 treatment should not be given","source":{"url":"https://www.uclh.nhs.uk/patients-and-visitors/patient-information-pages/information-adults-having-lutetium-lu-177-treatment","host":"uclh.nhs.uk","quote":"You should not have Lu-177 treatment if you are pregnant or breastfeeding.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}}],"checked_at":"2026-11-17","next_check_at":"2027-11-17","version":1}},"parsed_details":{"procedure_type":"therapy","fields":{"anesthesia":["none"],"back_to_work_days":{"min":1,"max":7,"unit":"days","qualifier":"Most resume office work within days; local radiation-safety rules limiting close contact may apply."},"complication_rate_pct":{"min":10,"max":55,"unit":"percent","qualifier":"Grade 3-4 adverse events in pivotal trials, mainly blood count drops; mild fatigue and nausea are far more common."},"contraindications":["Pregnancy (absolute)","Breastfeeding (must be stopped)","Lack of target uptake on PSMA or somatostatin receptor imaging","Severe bone marrow suppression","Severely impaired kidney function (relative or absolute depending on severity)","Severe liver dysfunction","Urinary obstruction or incontinence (relative)","Life expectancy too short to benefit"],"days_in_clinic":{"min":0,"max":1,"unit":"nights","qualifier":"Per cycle; usually same-day discharge; isolation stay may be needed under radiation rules."},"diagnostic_duration_minutes":null,"diagnostic_preparation":null,"diagnostic_referral_needed":null,"diagnostic_result_time_hours":null,"exercise_resume_weeks":{"min":0,"max":1,"unit":"weeks","qualifier":"Light activity usually resumes within days as fatigue allows; depends on tolerance and radiation precautions."},"final_result_months":{"min":3,"max":6,"unit":"months","qualifier":"Typical time to assess response after a full course of cycles, with imaging and biomarkers; varies by disease."},"fly_home_after_days":{"min":1,"max":2,"unit":"days","qualifier":"Usually the day after infusion once radiation-release criteria are met; air travel may trigger detectors, so carry a treatment letter."},"follow_up_visits":[{"purpose":"assessment","requirement":"routine","after":{"min":14,"max":28,"unit":"days","qualifier":"Blood tests (blood counts, kidney and liver function) in the weeks after the first cycle."}},{"purpose":"result_review","requirement":"routine","after":{"min":84,"max":180,"unit":"days","qualifier":"Response imaging and biomarkers after the cycles are completed."}}],"indications":["Metastatic castration-resistant prostate cancer with PSMA-positive disease (Lu-PSMA)","Well-differentiated gastroenteropancreatic neuroendocrine tumours with somatostatin receptor expression (Lu-DOTATATE)","Progressive inoperable/metastatic disease after other therapies, imaging-confirmed uptake"],"main_risks":["Fatigue and nausea","Bone marrow suppression (anaemia, low platelets, low white cells)","Dry mouth (Lu-PSMA)","Kidney toxicity","Rare liver toxicity","Tumour flare or hormonal crisis (neuroendocrine tumours)","Rare long-term myelodysplastic syndrome or leukaemia","Radiation exposure to others, needing precautions"],"pain":"Minimal procedural pain, only from IV cannulation; some patients have transient bone pain flare or nausea after infusion.","preparation":["Confirm target expression on PSMA or somatostatin receptor PET imaging","Baseline blood counts, kidney and liver function tests","Hydration on the day of treatment","Amino acid infusion for kidney protection (Lu-DOTATATE)","Anti-nausea medication before infusion","Review of current medications by the treating team"],"recovery_timeline":[{"phase":"Day of infusion","description":"IV infusion over about 30 minutes to 4 hours depending on protocol, with observation, then discharge.","restrictions":["Follow radiation safety precautions","Use a separate toilet where possible and flush twice"]},{"phase":"First week","description":"Possible fatigue, nausea and dry mouth; radiation precautions continue.","restrictions":["Limit close contact with others as instructed","Avoid contact with pregnant women and children as instructed"]},{"phase":"Weeks 2 to 6","description":"Blood count nadir and monitoring; fatigue gradually improves before the next cycle. Report fever, bleeding or severe fatigue.","restrictions":[]}],"rehabilitation_days":{"min":2,"max":7,"unit":"days","qualifier":"Ordinary functional recovery after each cycle, mainly fatigue resolving."},"result_longevity":"The effect is disease control, not a cure. How long it lasts varies by disease, radioligand, disease burden and line of therapy.","revision_rate_pct":null,"scars":"There are no scars; the only mark is a small puncture site from the intravenous cannula.","sessions_or_stages":{"sessions":{"min":4,"max":6,"unit":"visits","qualifier":"Treatment cycles in a typical course; actual number depends on protocol, response and tolerance."},"stages":[{"code":"cycle_1","label":"First infusion cycle","after":{"min":0,"max":0,"unit":"days","qualifier":"Start of treatment."}},{"code":"subsequent_cycles","label":"Subsequent cycles repeated every 6 to 8 weeks","after":{"min":42,"max":56,"unit":"days","qualifier":"Second cycle timing from the first; later cycles follow at similar intervals."}}],"qualifier":"Typical protocols use 4 to 6 cycles at 6 to 8 week intervals, depending on the radioligand."},"success":{"metric":"Progression-free survival at 20 months with Lu-177-DOTATATE versus high-dose octreotide (control 10.8%)","value":65.2,"unit":"percent","horizon":"20 months","evidence_status":"proven","population":"Adults with progressive, inoperable, somatostatin-receptor-positive midgut neuroendocrine tumours"},"techniques":[{"name":"Lu-177 PSMA-617 (Lu-PSMA) radioligand therapy","suits_whom":"Adults with PSMA-positive metastatic castration-resistant prostate cancer after prior therapy.","recovery":"Outpatient infusion; fatigue and dry mouth are common for days to weeks."},{"name":"Lu-177 DOTATATE peptide receptor radionuclide therapy","suits_whom":"Adults with somatostatin receptor-positive neuroendocrine tumours.","recovery":"Same-day or short stay; amino acid co-infusion; fatigue and nausea settle in days."}],"treatment_conditions":["day_case"],"treatment_duration_hours":{"min":1,"max":5,"unit":"hours","qualifier":"Lu-PSMA visit takes about 1–3 hours; Lu-DOTATATE visit about 4–5 hours including amino acid infusion and observation."},"initial_assessment_documents":["PSMA or DOTATATE PET/CT report and images","Biopsy histopathology report","Recent blood counts and kidney function tests","Liver function tests","Summary of prior cancer treatments","Recent CT or MRI reports (if available)"],"travel_trips":{"min":4,"max":6,"one_trip_possible":false,"qualifier":"One trip per cycle, given 6-8 weeks apart; stay 1-2 days, longer if isolation is required."},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Check the qualifications of the medical team treating you","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Have you checked the qualifications of the medical team treating you?","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C2","text":"Ask the treating doctor your questions about the treatment","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Have you been able to ask them questions about your treatment?","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C3","text":"Ask whether a doctor is always present in the clinic and whether a high dependency or intensive care unit exists","scope":"treatment_abroad","source":{"url":"https://www.bapras.org.uk/public/patient-information/cosmetic-surgery/cosmetic-surgery-abroad","host":"bapras.org.uk","quote":"Is there always a doctor in the clinic and is there a high dependency or intensive care unit?","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C4","text":"Confirm the surgeon is trained and experienced in the exact procedure you are considering, not just in surgery generally","scope":"treatment_abroad","source":{"url":"https://www.isaps.org/discover/patients-home/considering-your-procedure-abroad/finding-a-surgeon-abroad/","host":"isaps.org","quote":"Verify that the surgeon is trained and experienced in performing the procedure you are considering.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C5","text":"Expect two consultations with the treating surgeon before any surgery, which also gives you time to reconsider","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/conditions/cosmetic-procedures/cosmetic-surgery-abroad/","host":"nhs.uk","quote":"You should have 2 consultations with the surgeon treating you before any surgery.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"Only a helpline, not a named doctor, is offered for complications","scope":"treatment_abroad","source":{"url":"https://www.rcseng.ac.uk/patient-care/cosmetic-surgery/having-surgery-abroad","host":"rcseng.ac.uk","quote":"Make sure you have the contact details of a named doctor who can deal with any complications rather than a helpline.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"F2","text":"An advert or information that guarantees complete success should raise concerns","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Any advert or information that guarantees complete success should raise concerns.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F3","text":"Forceful persuasion or cheap, time-limited offers pushing you into a quick decision","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"warning_signs":{"status":"ok","items":[{"id":"W1","text":"Vomiting blood or bleeding you cannot stop","urgency":"emergency","general":false,"source":{"url":"https://www.mskcc.org/cancer-care/patient-education/medications/adult/lutetium-lu-177-vipivotide-tetraxetan","host":"mskcc.org","quote":"Signs of bleeding like throwing up or coughing up blood; vomit that looks like coffee grounds; blood in the urine; black, red, or tarry stools; bleeding from the gums; abnormal vaginal bleeding; bruises without a cause or that get bigger; or bleeding you cannot stop.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W2","text":"Unable to pass urine","urgency":"contact_clinic","general":false,"source":{"url":"https://www.mskcc.org/cancer-care/patient-education/medications/adult/lutetium-lu-177-vipivotide-tetraxetan","host":"mskcc.org","quote":"Signs of kidney problems like unable to pass urine, change in how much urine is passed, blood in the urine, or a big weight gain.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W3","text":"Fever, chills, or sore throat","urgency":"contact_clinic","general":true,"source":{"url":"https://my.clevelandclinic.org/health/drugs/23722-lutetium-lu-177-vipivotide-tetraxetan-injection","host":"my.clevelandclinic.org","quote":"Call your care team for advice if you get a fever, chills, sore throat, or other symptoms of a cold or flu.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"take_home":{"status":"ok","items":[{"id":"T1","text":"Tells home clinicians radiation may persist up to two months after therapy","document":"radioactive medicine card","source":{"url":"https://www.mskcc.org/cancer-care/patient-education/about-your-pluvicto-treatment","host":"mskcc.org","quote":"It says you can give off small amounts of radioactivity for up to 2 months after your treatment.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T2","text":"Home doctor needs the clinic's follow-up recommendations in a written discharge summary","document":"discharge summary","source":{"url":"https://sbuhb.nhs.wales/about-us/individual-patient-commissioning/ipc-folder/advice-on-accessing-treatment-abroad","host":"sbuhb.nhs.wales","quote":"When you have treatment abroad, you must ask the treatment provider for their follow-up recommendations documented within a written discharge summary in English.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"alternatives":{"status":"ok","items":[{"id":"A1","text":"Surgery is not an option for your neuroendocrine tumor","name":"Hormone therapy medications","source":{"url":"https://my.clevelandclinic.org/health/treatments/24073-peptide-receptor-radionuclide-therapy-prrt","host":"my.clevelandclinic.org","quote":"If surgery isn’t an option, people with NETs may receive hormone therapy medications.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200},"operation_id":null}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"technique_details":{"status":"ok","items":[{"id":"lu-177-psma-617-radioligand","name":"Lu-177 PSMA-617 (Lu-PSMA) radioligand therapy","how_it_works":{"text":"A radioactive drug targets cancer cells and delivers radiation directly to them","source":{"url":"https://medlineplus.gov/druginfo/meds/a622063.html","host":"medlineplus.gov","quote":"It works by targeting and delivering radiation directly to cancer cells which damages and kills these cells.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}},{"id":"lu-177-dotatate-peptide","name":"Lu-177 DOTATATE peptide receptor radionuclide therapy","how_it_works":{"text":"A radioactive drug enters tumor cells that carry somatostatin receptors","source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2018/lutathera-fda-gastrointestinal-nets","host":"cancer.gov","quote":"The drug then enters these somatostatin receptor−positive tumor cells,","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"preop_tests":{"status":"ok","items":[{"id":"T1","name":"PET scan","aliases":["PET scan","PSMA PET","DOTATATE PET","somatostatin receptor PET imaging","PET imaging","PET/CT"],"kind":"imaging","origin":[{"field":"preparation","text":"Confirm target expression on PSMA or somatostatin receptor PET imaging"},{"field":"initial_assessment_documents","text":"PSMA or DOTATATE PET/CT report and images"}],"what_it_checks":{"text":"Shows where the tumor is and how well the ligand binds","source":{"url":"https://snmmi.org/MWM/Patients/Procedures/177Lu-PSMA-617-Therapy-Pluvicto.aspx","host":"snmmi.org","quote":"The PSMA ligand is similar to the one used for therapy but uses a different type of radioactive material that provides an image (PET/CT) to show where the tumor is and how well the ligand attaches to it.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":{"text":"Wait 45 to 60 minutes after the arm vein injection before the scan","source":{"url":"https://snmmi.org/MWM/Patients/Procedures/177Lu-PSMA-617-Therapy-Pluvicto.aspx","host":"snmmi.org","quote":"For this procedure, you will receive an injection into an arm vein and will wait 45-60 minutes to allow it to circulate before undergoing the scan.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}}},{"id":"T2","name":"Complete blood count","aliases":["Complete blood count","CBC","blood counts","full blood count"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood counts, kidney and liver function tests"},{"field":"initial_assessment_documents","text":"Recent blood counts and kidney function tests"}],"what_it_checks":{"text":"Checks red cells, white cells and platelets, which therapy can lower","source":{"url":"https://snmmi.org/MWM/Patients/Procedures/177Lu-PSMA-617-Therapy-Pluvicto.aspx","host":"snmmi.org","quote":"The radiation may cause a decrease in your red cells, white cells, platelets, liver or kidney function.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"type":"always","text":"Always","source":{"url":"https://snmmi.org/MWM/Patients/Procedures/177Lu-PSMA-617-Therapy-Pluvicto.aspx","host":"snmmi.org","quote":"Several days before each treatment, you will need to undergo blood to make sure it is safe to proceed.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"test_prep":null},{"id":"T3","name":"Kidney function test","aliases":["Kidney function test","kidney function tests","renal function test","renal function tests"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood counts, kidney and liver function tests"},{"field":"initial_assessment_documents","text":"Recent blood counts and kidney function tests"}],"what_it_checks":{"text":"Checks kidney function, which the radiation can decrease","source":{"url":"https://snmmi.org/MWM/Patients/Procedures/177Lu-PSMA-617-Therapy-Pluvicto.aspx","host":"snmmi.org","quote":"The radiation may cause a decrease in your red cells, white cells, platelets, liver or kidney function.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"type":"always","text":"Always","source":{"url":"https://snmmi.org/MWM/Patients/Procedures/177Lu-PSMA-617-Therapy-Pluvicto.aspx","host":"snmmi.org","quote":"Several days before each treatment, you will need to undergo blood to make sure it is safe to proceed.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"test_prep":null},{"id":"T4","name":"Liver function test","aliases":["Liver function test","liver function tests","LFT","LFTs"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood counts, kidney and liver function tests"},{"field":"initial_assessment_documents","text":"Liver function tests"}],"what_it_checks":{"text":"Checks liver function, which the radiation can decrease","source":{"url":"https://snmmi.org/MWM/Patients/Procedures/177Lu-PSMA-617-Therapy-Pluvicto.aspx","host":"snmmi.org","quote":"The radiation may cause a decrease in your red cells, white cells, platelets, liver or kidney function.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"type":"always","text":"Always","source":{"url":"https://snmmi.org/MWM/Patients/Procedures/177Lu-PSMA-617-Therapy-Pluvicto.aspx","host":"snmmi.org","quote":"Several days before each treatment, you will need to undergo blood to make sure it is safe to proceed.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"test_prep":null},{"id":"T5","name":"CT scan","aliases":["CT scan","CT","computed tomography"],"kind":"imaging","origin":[{"field":"initial_assessment_documents","text":"Recent CT or MRI reports (if available)"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T6","name":"MRI scan","aliases":["MRI scan","MRI","magnetic resonance imaging"],"kind":"imaging","origin":[{"field":"initial_assessment_documents","text":"Recent CT or MRI reports (if available)"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T7","name":"Blood tests","aliases":["Blood tests"],"kind":"lab","origin":[{"field":"packages","text":"Blood tests"}],"what_it_checks":{"text":"Checks red cells, white cells, platelets, liver and kidney function","source":{"url":"https://snmmi.org/MWM/Patients/Procedures/177Lu-PSMA-617-Therapy-Pluvicto.aspx","host":"snmmi.org","quote":"These include tests for your red cells, white cells, platelets, liver and kidney function.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"type":"always","text":"Always","source":{"url":"https://snmmi.org/MWM/Patients/Procedures/177Lu-PSMA-617-Therapy-Pluvicto.aspx","host":"snmmi.org","quote":"Several days before each treatment, you will need to undergo blood to make sure it is safe to proceed.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"test_prep":{"text":"Have blood testing several days before each treatment","source":{"url":"https://snmmi.org/MWM/Patients/Procedures/177Lu-PSMA-617-Therapy-Pluvicto.aspx","host":"snmmi.org","quote":"Several days before each treatment, you will need to undergo blood to make sure it is safe to proceed.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}}}],"checked_at":"2026-11-17","next_check_at":"2027-11-17","version":1},"prep_in_advance":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-17","next_check_at":"2027-02-15"},"visit_and_day":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-17","next_check_at":"2027-02-15"},"if_something_changes":{"status":"ok","items":[{"id":"S1","text":"Pregnancy or breastfeeding should be reported because Lu-177 treatment should not be given","source":{"url":"https://www.uclh.nhs.uk/patients-and-visitors/patient-information-pages/information-adults-having-lutetium-lu-177-treatment","host":"uclh.nhs.uk","quote":"You should not have Lu-177 treatment if you are pregnant or breastfeeding.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}}],"checked_at":"2026-11-17","next_check_at":"2027-11-17","version":1}}},"techniques":[{"id":"lu-177-psma-617-radioligand","name":"Lu-177 PSMA-617 (Lu-PSMA) radioligand therapy","how_it_works":{"id":"H1","text":"A radioactive drug targets cancer cells and delivers radiation directly to them","source":{"url":"https://medlineplus.gov/druginfo/meds/a622063.html","host":"medlineplus.gov","quote":"It works by targeting and delivering radiation directly to cancer cells which damages and kills these cells.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Adults with PSMA-positive metastatic castration-resistant prostate cancer after prior therapy.","price_from":10000,"recovery":"Outpatient infusion; fatigue and dry mouth are common for days to weeks."},{"id":"lu-177-dotatate-peptide","name":"Lu-177 DOTATATE peptide receptor radionuclide therapy","how_it_works":{"id":"H1","text":"A radioactive drug enters tumor cells that carry somatostatin receptors","source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2018/lutathera-fda-gastrointestinal-nets","host":"cancer.gov","quote":"The drug then enters these somatostatin receptor−positive tumor cells,","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Adults with somatostatin receptor-positive neuroendocrine tumours.","price_from":10000,"recovery":"Same-day or short stay; amino acid co-infusion; fatigue and nausea settle in days."}],"alternatives":{"status":"ok","items":[{"id":"A1","text":"Surgery is not an option for your neuroendocrine tumor","name":"Hormone therapy medications","source":{"url":"https://my.clevelandclinic.org/health/treatments/24073-peptide-receptor-radionuclide-therapy-prrt","host":"my.clevelandclinic.org","quote":"If surgery isn’t an option, people with NETs may receive hormone therapy medications.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200},"operation_id":null}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"diagnostic":{"status":"not_applicable"},"country":{"why":{"status":"ok","items":[{"id":"Y1","text":"Turkey's Ministry of Health publishes lists of authorized healthcare providers and facilitators holding authorization certificates","specialties":[],"source":{"url":"https://shgmturizmdb.saglik.gov.tr/EN-69410/announcements.html","host":"shgmturizmdb.saglik.gov.tr","quote":"Updated lists of healthcare providers and facilitators that have been granted authorization certificates by the Ministry","tier":"government","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-05-11","version":1},"travel":{"status":"ok","items":[{"id":"V1","item":"visa","audience":"uk","volatile":true,"text":"UK citizen passport holders can visit Turkey without a visa for up to 90 days in any 180-day period, for business or tourism","source":{"url":"https://www.gov.uk/foreign-travel-advice/turkey/entry-requirements","host":"gov.uk","quote":"You can visit Turkey without a visa for up to 90 days in any 180-day period, for business or tourism.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V2","item":"visa","audience":"us","volatile":true,"text":"US ordinary passport holders are exempt from a visa for up to 90 days in any 180-day period in Turkey","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Turkey.html","host":"travel.state.gov","quote":"Ordinary passport holders are exempted from visa up to 90 days in any 180-day period.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V3","item":"passport_validity","audience":"uk","volatile":true,"text":"A UK passport must expire at least 150 days after arrival in Turkey and have at least 1 blank page","source":{"url":"https://www.gov.uk/foreign-travel-advice/turkey/entry-requirements","host":"gov.uk","quote":"To enter Turkey, your passport must have an ‘expiry date’ at least 150 days after the date you arrive and at least 1 blank page.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V4","item":"passport_validity","audience":"us","volatile":true,"text":"A US passport must be valid for six months beyond the entry date into Turkey","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Turkey.html","host":"travel.state.gov","quote":"Passports must be valid for six months beyond your entry date.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V5","item":"prescriptions","audience":"uk","volatile":false,"text":"British prescriptions are not accepted in pharmacies in Turkey","source":{"url":"https://www.gov.uk/foreign-travel-advice/turkey/health","host":"gov.uk","quote":"British prescriptions are not accepted in pharmacies in Turkey.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V6","item":"emergency_number","audience":"all","volatile":false,"text":"Dial 112 and ask for an ambulance in Turkey","source":{"url":"https://www.gov.uk/foreign-travel-advice/turkey/health","host":"gov.uk","quote":"Dial 112 and ask for an ambulance.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-11","next_check_at":"2026-12-11","version":1},"other_countries_with_page":["austria","china","germany","india","israel","spain"]},"often_combined_with":{"status":"missing","reason":"not_collected"},"reviews":{"avg_rating":4.55,"count":2384,"scope":"clinic","rating_scale":5,"pros":{"status":"missing","reason":"not_collected"},"cons":{"status":"missing","reason":"not_collected"}},"current":{"seo_text":"<p>Lutetium-177 therapy in Turkey typically costs from _op_830_price_from_ to _op_830_price_to_ per session. The final price depends on the specific radiopharmaceutical used, such as PSMA or DOTATATE, and inclusion of diagnostic PET-CT scans. Patients save significantly compared to the US, where the average price is _price_compare_US_average_, representing a savings of approximately _price_percent_discount_%. Turkish packages often include hospitalization, blood tests, and VIP transfers.</p>\n\n<ul>\n<li><strong>PSMA therapy with PET-CT:</strong> Typically costs more as it bundles the required diagnostic imaging.</li>\n<li><strong>DOTA Neuroendocrine program:</strong> Often priced higher due to specialized protocols for neuroendocrine tumors.</li>\n<li><strong>Hospitalization tier:</strong> Specialized nuclear medicine ward stays for radiation monitoring impact the total cost.</li>\n<li><strong>Geographic hubs:</strong> Most high-volume centers for this therapy are located in Istanbul and Antalya.</li>\n</ul>\n\n<p><strong>Bookimed Expert Insight:</strong> Choosing a JCI-accredited facility like Memorial Şişli or Anadolu Medical Center ensures top-tier safety. Anadolu is even affiliated with Johns Hopkins Hospital, providing US-standard protocols at much lower rates. For better value, look for packages around $12,150 that already include the necessary PET-CT scans. This prevents extra diagnostic costs after arrival and simplifies the entire treatment journey.</p>","faq":[{"q":"Who is eligible for Lutetium-177 therapy in Turkey?","a":"<p>Eligibility for Lutetium-177 therapy in Turkey requires a diagnosis of metastatic castration-resistant prostate cancer or advanced neuroendocrine tumors. Candidates must demonstrate high target expression via Ga-68 PSMA or DOTATATE PET-CT scans and have exhausted standard treatments like chemotherapy or hormone therapy while maintaining stable organ function.</p> <ul> <li><strong>Disease stage:</strong> Indicated for metastatic cancers resistant to conventional hormonal or chemical treatments.</li> <li><strong>Diagnostic requirement:</strong> Mandatory PET-CT scans must confirm high PSMA or somatostatin receptor expression.</li> <li><strong>Organ health:</strong> Patients requires adequate kidney, liver, and bone marrow reserves for safety.</li> <li><strong>Performance status:</strong> Candidates must be healthy enough for travel and 1-day hospital stays.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While many expect Lu-177 for prostate cancer only, Turkish centers like Anadolu Medical Center and Memorial Şişli offer specialized DOTA therapy for neuroendocrine tumors. Patients can save significantly as Turkish therapy costs _op_830_price_from_ to _op_830_price_to_, compared to the US average of _price_compare_US_average_.</p> <p><strong>Patient Consensus:</strong> Patients emphasize that documentation in English speeds up eligibility tallies. Many feel relieved after nuclear medicine specialists simplify complex physics into clear, actionable treatment steps.</p>"},{"q":"What is the success rate of Lutetium-177 therapy?","a":"<p>Lutetium-177 therapy demonstrates a biochemical success rate between 40% and 66% for metastatic castration-resistant prostate cancer. Success is measured by a 50% reduction in prostate-specific antigen levels. Notable outcomes include extending median overall survival to 15.3 months in patients at JCI-accredited centers.</p> <ul> <li><strong>Survival extension:</strong> Median overall survival reaches 15.3 months compared to 11.3 with standard care.</li> <li><strong>Progression-free survival:</strong> Patients typically remain progression-free for 8.7 months, doubling the standard 3.4 months.</li> <li><strong>Tumor reduction:</strong> Objective response rates show measurable tumor shrinkage in 30% to 36.6% of cases.</li> <li><strong>Pain management:</strong> Clinical benefit for bone-related pain is reported in 54% to 88% of patients.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While many focus on the 66% success rate, the real differentiator in Turkey is the mandatory pre-treatment screening. Facilities like Anadolu Medical Center require MAG-3 Renal Scintigraphy and DOTA PET scans to ensure kidney safety and high receptor uptake. This specialized protocol helps prevent treatment failure in patients with low tracer affinity.</p> <p><strong>Patient Consensus:</strong> Patients report a 70-80% PSA reduction after 4-6 cycles but emphasize that a PSMA-PET scan is essential first to confirm eligibility. Many highlight that managing salivary gland dryness and fatigue is the primary practical challenge during the 18-24 month survival extension.</p>"},{"q":"What are the common side effects of Lutetium-177 therapy?","a":"<p>Lutetium-177 therapy results in mild to moderate side effects including persistent fatigue, dry mouth, and temporary nausea. Targeted radionuclide treatments like PSMA or DOTA therapy commonly cause bone marrow suppression, leading to lower blood cell counts during the 4–6 week recovery timeline.</p> <ul> <li><strong>Hematologic impact:</strong> Temporary drops in white blood cells and platelets require frequent blood monitoring.</li> <li><strong>Salivary glands:</strong> Radioligands can affect salivary tissues, potentially causing dry mouth or xerostomia.</li> <li><strong>Gastrointestinal response:</strong> Patients often report nausea, loss of appetite, or altered taste after infusion.</li> <li><strong>Fatigue levels:</strong> Significant exhaustion typically peaks 1–2 weeks post-treatment and lasts several weeks.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Data from top-rated centers like Memorial Şişli Hospital and Anadolu Medical Center shows that fatigue often compounds with each cycle. While the first session is usually well-tolerated, the third and fourth treatments typically produce more pronounced side effects. Patients should prioritize hydration during these later cycles to support kidney function, as clinics like Anadolu Medical Center frequently include MAG-3 Renal Scintigraphy in their $10,000–$13,000 packages to monitor this specific risk.</p> <p><strong>Patient Consensus:</strong> Patients report that while the radioactive treatment sounds intimidating, the immediate experience is often calm. Most find that fatigue is the primary challenge, significantly impacting daily activities for about a month after each session.</p>"},{"q":"What radiation safety precautions are taken after each cycle?","a":"<p>Post-cycle safety protocols for Lutetium-177 therapy in Turkey focus on the ALARA principle to minimize radiation exposure via distance and hygiene. Patients typically undergo 24-48 hours of monitored isolation at JCI-accredited facilities like Memorial Şişli or Anadolu Medical Center before returning to public environments.</p> <ul> <li><strong>Distance management:</strong> Maintain 3–6 feet from others and sleep separately for 7–11 days post-infusion.</li> <li><strong>Waste protocols:</strong> Flush toilets 2–3 times after use and sit while urinating to prevent splashes.</li> <li><strong>Hygiene habits:</strong> Wash hands frequently and launder clothes separately for at least 7 days.</li> <li><strong>Vulnerable groups:</strong> Strictly avoid close contact with children and pregnant women for 1–2 weeks.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While many international centers follow generic 24-hour discharge rules, top Turkish clinics like Anadolu Medical Center utilize personalized dosimetry. This means Prof. Dr. Kezban Berberoglu or similar experts calculate your specific radiation clearance rate. Instead of guessing, ask for your specific clearance numbers to potentially shorten your isolation period safely.</p> <p><strong>Patient Consensus:</strong> Patients emphasize requesting written safety protocols early, as verbal instructions can be confusing. Many suggest confirming specific return-to-work timelines and bathroom cleaning steps to ensure household safety.</p>"},{"q":"How many treatment cycles are typically needed?","a":"<p>Patients typically receive 4 to 6 cycles of Lutetium-177 therapy in Turkey to achieve optimal results for metastatic prostate cancer or neuroendocrine tumors. Each cycle is spaced 6 to 8 weeks apart, allowing healthy tissues like bone marrow and kidneys to recover between administrations.</p> <ul> <li><strong>Treatment frequency:</strong> Cycles occur every 6 to 8 weeks to manage cumulative radiation exposure safely.</li> <li><strong>Success monitoring:</strong> Clinics use PSMA PET-CT scans and blood PSA levels to evaluate response.</li> <li><strong>Clinical standard:</strong> Protocols often follow the VISION trial, recommending up to 6 total infusions.</li> <li><strong>Individual adjustment:</strong> Specialists may reduce cycles to 2 or 3 if early remission is confirmed.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While base prices for Lutetium-177 in Turkey range from _op_830_price_from_ to _op_830_price_to_ per cycle, the real advantage lies in the diagnostic bundling. Clinics like Anadolu Medical Center, which is Johns Hopkins-affiliated, frequently include specialized MAG-3 renal scintigraphy in the first cycle. This is critical because it confirms your kidneys can process the isotope before you commit to a full 4 or 6-cycle treatment plan.</p> <p><strong>Patient Consensus:</strong> Patients value the clear technical explanations provided by Turkish nuclear medicine specialists, which help reduce anxiety about radiation. Many highlight that the significant savings—often _price_percent_discount_% compared to US costs—make completing the full 6-cycle protocol financially feasible.</p>"},{"q":"What leading centers in Turkey offer Lutetium-177 therapy?","a":"<p>Leading Turkish centers for Lutetium-177 therapy include Anadolu Medical Center, Memorial Şişli Hospital, and Hisar Hospital Intercontinental. These Istanbul-based facilities specialize in Lu-177 PSMA for prostate cancer and Lu-177 DOTA for neuroendocrine tumors, featuring Joint Commission International (JCI) accreditation and specialized nuclear medicine units.</p> <ul> <li><strong>Anadolu Medical Center:</strong> Affiliated with Johns Hopkins Medicine, offering FDA-approved DOTA PET/CT and PSMA imaging.</li> <li><strong>Memorial Şişli Hospital:</strong> Features experts like Prof. Cuneyt Turkmen who has performed over 1,100 procedures.</li> <li><strong>Hisar Hospital:</strong> Provides targeted PSMA therapy packages led by MD Anderson-trained oncology specialists.</li> <li><strong>Liv Hospital Ulus:</strong> Home to nuclear medicine experts with over 30 years of clinical experience.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While many clinics offer Lutetium therapy, Anadolu Medical Center stands out because it maintains on-site Lu-177 production. This ensures treatment reliability and prevents delays caused by isotope transport, which is a common logistical hurdle for international patients seeking molecular radiotherapy.</p> <p><strong>Patient Consensus:</strong> Patients frequently highlight the clear clinical explanations provided by Turkish nuclear physicists, which help ease anxiety before the first cycle. While most report speedy treatment processes, some advise preparing for common manageable side effects like fatigue or temporary dry mouth.</p>"},{"q":"What is included in a typical international treatment package for Lutetium-177 therapy in Turkey?","a":"<p>International Lutetium-177 packages in Turkey provide a complete clinical cycle, covering the radioactive drug administration, PSMA or DOTA PET-CT imaging, and specialized radiation monitoring. Medical tourists receive VIP airport transfers, multilingual coordination, and 1 night of hospitalization in lead-lined rooms at JCI-accredited facilities like Memorial Şişli.</p> <ul> <li><strong>Medical diagnostics:</strong> Includes PSMA PET-CT imaging and MAG-3 renal scintigraphy for dose planning.</li> <li><strong>Hospital stay:</strong> Provides 1 night in a dedicated nuclear medicine ward for radiation safety.</li> <li><strong>Laboratory tests:</strong> Covers essential blood work including kidney, liver, and hematologic function profiles.</li> <li><strong>Logistics support:</strong> Includes VIP airport-to-clinic transfers and on-site personal translation services.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Anadolu Medical Center stands out by maintaining a formal clinical affiliation with Johns Hopkins Hospital. Their high-tier packages often include MAG-3 renal scintigraphy specifically during the first treatment cycle. This extra step ensures your kidneys can safely process the radiation before proceeding with subsequent doses.</p> <p><strong>Patient Consensus:</strong> Patients frequently highlight the relief of having a translator explain complex nuclear physics simply. Most report that the seamless coordination between airport pickups and hospital check-ins reduces the stress of traveling for cancer care.</p>"}],"h2":[{"text":"Quel est le Coût pour votre Thérapie au lutétium-177 en Turquie ?","kind":"content"},{"text":"Vos avantages et garanties avec Bookimed","kind":"content"},{"text":"Votre coordinateur médical personnel","kind":"content"},{"text":"Ne Manquez pas les Offres Exclusives de thérapie au lutétium-177 en Turquie en novembre 2026","kind":"content"},{"text":"Découvrez les Meilleures Cliniques pour Votre Thérapie au lutétium-177 en Turquie : 6 Options Vérifiées et Prix","kind":"content"},{"text":"Aperçu de thérapie au lutétium-177 en Turquie","kind":"content"},{"text":"Obtenez une Évaluation Médicale pour Votre Thérapie au lutétium-177 en Turquie : Consultez Maintenant 10 Médecins Expérimentés","kind":"content"},{"text":"Histoires vidéo des patients de Bookimed","kind":"content"},{"text":"Avis sur Bookimed : Découvrez l'Expérience des Patients","kind":"content"},{"text":"Partager ce contenu","kind":"content"},{"text":"FAQ de thérapie au lutétium-177 en Turquie","kind":"content"},{"text":"Obtenez une consultation gratuite","kind":"content"}]},"placeholders":{"price_from":"{{price_from}}","clinics_count":"{{clinics_count}}","cities_count":"{{cities_count}}","savings_pct":"{{savings_pct}}","data_date":"{{data_date}}"},"legal":{"restricted_markets":{"status":"missing","reason":"not_collected"}},"conflicts":[]}